Linda C Surh

Summary

Publications

  1. ncbi Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs
    Linda C Surh
    Global Regulatory Affairs, GlaxoSmithKline, UK
    Pharmacogenomics 11:1637-47. 2010
  2. ncbi Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with 'what-ifs'
    Linda C Surh
    CEDD, Global Regulatory Affairs, Neurology and Pharmacogenetics, GlaxoSmithKline, Greenford Road, Greenford, Middlesex, UB6 OHE, UK
    Pharmacogenomics 10:137-47. 2009

Detail Information

Publications2

  1. ncbi Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs
    Linda C Surh
    Global Regulatory Affairs, GlaxoSmithKline, UK
    Pharmacogenomics 11:1637-47. 2010
    ....
  2. ncbi Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with 'what-ifs'
    Linda C Surh
    CEDD, Global Regulatory Affairs, Neurology and Pharmacogenetics, GlaxoSmithKline, Greenford Road, Greenford, Middlesex, UB6 OHE, UK
    Pharmacogenomics 10:137-47. 2009
    ..All converge onto a label that must communicate evidence-based use of a new medicine that is effective and safe...